Global Anti-Vascular Endothelial Growth Factor Therapeutics Market to reach USD 12.09 billion by 2027.Global Anti-Vascular Endothelial Growth Factor Therapeutics Market is valued approximately at USD 11.67 billion in 2020 and is anticipated to grow with a healthy growth rate of more than 0.5% over the forecast period 2021-2027. Anti-vascular endothelial growth factor is a regulator of the angiogenesis during the growth and development in disease states such as cancer, diabetes, and macular degeneration. The global anti-vascular endothelial growth factor therapeutics market is being driven by growth in prevalence of various ophthalmic diseases such as macular edema, diabetic retinopathy, retinal vein occlusion, and Age-related Macular Degeneration (AMD) along with rise in geriatric population. Furthermore, initiatives by market players such as product launches and research technological advancements, will provide new opportunities for the global anti-vascular endothelial growth factor therapeutics industry. For instance, according to the report of WHO published in 2021, about 196 million people have been affected by AMD across the world, which also includes around 10.4 million cases with a moderate to severe vision impairment. As a result, increased in ophthalmic diseases will necessitate the use will serve as a catalyst for the Anti-Vascular Endothelial Growth Factor Therapeutics industry in the future. However, low screening rates and the rates of diagnostic of diabetic retinopathy in developing nations, may impede market growth over the forecast period of 2021-2027.

Asia Pacific, North America, Europe, Latin America, and Rest of the World are the key regions considered for the regional analysis of global anti-vascular endothelial growth factor therapeutics market. High disease prevalence, rising government measures, and technological advancements makes North America the leading region across the world in terms of market share. Whereas Asia Pacific is also anticipated to exhibit the highest growth rate over the forecast period 2021-2027, due to increase in penetration of anti-VEGF products, rising disposable income, and growing consumer awareness in the region.
Major market player included in this report are:

Hoffmann-la roche ltd
Bayer ag
Regeneron pharmaceuticals inc.
Novartis ag
Biogen
Coherus Biosciences
Pfizer Inc.
Viatris Inc
Amgen
Eli Lilly and company

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Device:
Macular Edema
Diabetic Retinopathy
Retinal Vein Occlusion
Age-related Macular Degeneration
By Product:
Eylea
Lucentis
Beovu


By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027.

Target Audience of the Global Anti-Vascular Endothelial Growth Factor Therapeutics Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors